Is DexCom Inc. (NASDAQ:DXCM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating DexCom Inc. at current levels.
Stelo is building a second growth engine in a $60B+ population Dexcom has never monetized, and the stock is trading near trough valuation.
Where DXCM is headed
By late 2027, Dexcom will be running two distinct businesses under one roof. The first is the legacy insulin-using CGM franchise (G7, G7 15 Day, ONE+), which is still growing at low-to-mid teens as international expansion and pharmacy channel penetration fill in white space. The second is Stelo, a biosensor aimed at the roughly 25 million Americans with Type 2 diabetes not on insulin, plus a much larger prediabetes population that no CGM company has ever seriously addressed. Stelo launched as an over-the-counter product in 2024, but the real commercial unlock comes as employer health plans and GLP-1 prescribers start bundling glucose visibility with weight management programs. That second business barely registers in the revenue mix today, but it could be contributing $400M-$600M in annualized revenue within 18 months if distribution deals with pharmacy benefit managers and telehealth platforms convert at the rates management hinted at on the Q1 call.
Read the full Compass Direction on DXCM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $78.19).
See the full DXCM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DexCom Inc. (NASDAQ:DXCM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating DexCom Inc. at current levels. Stelo is building a second growth engine in a $60B+ population Dexcom has never monetized, and the stock is trading near trough valuation.
What is DXCM's Compass Score?
DexCom Inc. scores 91/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for DXCM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the DXCM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.